BioVersys BV100 gets US FDA Fast-Track Designation
BioVersys AG said the US FDA granted Fast-Track Designation for BV100. The company framed the designation as support for an urgent need for novel and innovative antimicrobials to treat serious infections.
BioVersys AG/ Key word(s): MiscellaneousBioVersys granted Fast-Track Designation from US FDA for BV10002.09.2026 / 07:00 CET/CESTBasel, Switzerland.
September 2, 2026, 7am CEST• Fast-Track Designation supports the urgent need for novel and innovative antimicrobials for the treatment of serious infe…